Viridian Therapeutics, Inc.\DE
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
VRDN$30.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share data)
| Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series B | |||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount | |||||||||||||||||||
| Balance as of December 31, 2025 | 134,864 | $61,188 | 79,620 | $70,868 | 101,826,500 | $1,018 | $1,927,104 | $447 | $(1,338,458) | $722,167 | |||||||||
| Issuance of common stock upon exercises of stock options | — | — | — | — | 424,648 | 5 | 6,352 | — | — | 6,357 | |||||||||
| Issuance of common stock upon vesting of restricted stock units | — | — | — | — | 206,946 | 2 | (2) | — | — | — | |||||||||
| Share-based compensation expense | — | — | — | — | — | — | 13,390 | — | — | 13,390 | |||||||||
| Unrealized loss on available-for-sale securities | — | — | — | — | — | — | — | (1,008) | — | (1,008) | |||||||||
| Change in cumulative translation adjustment | — | — | — | — | — | — | — | 3 | — | 3 | |||||||||
| Net loss | — | — | — | — | — | — | — | — | (104,901) | (104,901) | |||||||||
| Balance as of March 31, 2026 | 134,864 | $61,188 | 79,620 | $70,868 | 102,458,094 | $1,025 | $1,946,844 | $(558) | $(1,443,359) | $636,008 | |||||||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share data)
| Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series B | |||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount | |||||||||||||||
| Balance as of December 31, 2024 | 134,864 | $61,188 | 145,160 | $127,697 | 80,994,046 | $810 | $1,477,811 | $(10) | $(995,857) | $671,639 | |||||
| Issuance of common stock in at-the-market offerings, net of issuance costs of $149 | — | — | — | — | 245,388 | 3 | 4,792 | — | — | 4,795 | |||||
| Issuance of common stock upon exercises of warrants | — | — | — | — | 115,146 | 1 | 1,617 | — | — | 1,618 | |||||
| Issuance of common stock upon exercises of stock options | — | — | — | — | 185,426 | 2 | 2,295 | — | — | 2,297 | |||||
| Issuance of common stock under employee stock purchase plan | — | — | — | — | 41,106 | — | 561 | — | — | 561 | |||||
| Issuance of common stock upon vesting of restricted stock units | — | — | — | — | 8,315 | — | — | — | — | — | |||||
| Share-based compensation expense | — | — | — | — | — | — | 10,220 | — | — | 10,220 | |||||
| Unrealized gain on available-for-sale securities | — | — | — | — | — | — | — | 255 | — | 255 | |||||
| Net loss | — | — | — | — | — | — | — | — | (86,912) | (86,912) | |||||
| Balance as of March 31, 2025 | 134,864 | $61,188 | 145,160 | $127,697 | 81,589,427 | $816 | $1,497,296 | $245 | $(1,082,769) | $604,473 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.